Multiple Myeloma Progression
13
4
5
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
7.7%
1 terminated out of 13 trials
0.0%
-86.6% vs benchmark
0%
0 trials in Phase 3/4
0%
1 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (13)
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study
Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM)
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors
Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma
Tinostamustine Conditioning and Autologous Stem Cell
CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma
Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM